Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Get the next trade alert free. Vertex Pharmaceuticals Inc VRTX announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 ...

research-stage immunoprotective approaches - BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D ...

The therapy in question, dubbed VX-264, involves creating insulin-producing cells and surgically implanting them into people with Type 1 diabetes. Vertex has been conducting a phase 1/2 study of ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement. There were two primary endpoints in ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals Incorporated VRTX announced ... which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation ...

Zimislecel (formerly VX-880), Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients ...